A reanalysis of nanoparticle tumor delivery using classical pharmacokinetic metrics
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Interpretation of nanoparticle PK results can be markedly influenced by differing PK metrics selected.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Comparisons between %ID in tumor and traditional PK metrics for all datasets (i.e., all types of nanoparticles). Correlation plots for all datasets between %ID in tumor (per Wilhelm et al.) and AUCtumor/AUCblood ratio (%) (A), RDI-OT AUCtumor (B), and tumor Cmax (C). Plots are shown with all datasets (i, outliers shown as □) and with outliers excluded (ii). There was no relationship between %ID in tumor and AUCtumor/AUCblood ratio (%) [ρ = 0.183 all data (AD); ρ = 0.151 excluding outliers (EO)] and a weak relationship between %ID in tumor and RDI-OT AUCtumor (ρ = 0.319 AD; ρ = 0.289 EO). There was a moderate relationship between %ID in tumor and the tumor Cmax (ρ = 0.562 AD; ρ = 0.572 EO).](https://figures.cochat.ai/paper-figures/800c7ec305d0438ea04d8675852da227/a-reanalysis-of-nanoparticle-tumor-delivery-using-classical-pharmacokinetic-figure-1.jpg)




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The conclusion was that the %ID in tumor was poorly correlated with the standard PK metrics which describe nanoparticle tumor delivery (AUCtumor/AUCblood ratio).”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [244]
The cited source says what the claim attributes to it.
In the citing paper
“The relative tumor delivery of nanoparticles was ~100-fold greater as assessed by the standard AUCtumor/AUCblood ratio than by %ID in tumor.”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [244]
The cited source says what the claim attributes to it.
In the citing paper
“A recent reanalysis by Price et al., based on the same dataset, has cast major doubt on the validity of Wilhelm et al. conclusions [244].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [244]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of nanoparticle delivery to tumours
Wilhelm, S., Tavares, A. J., Dai, Q., Ohta, S., Audet, J., Dvorak, H. F., & Chan, W. C. W. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.14 · Cited by 5,218 · cited 3×
“(19) However, the conclusions of the study by Wilhelm et al.”
BackgroundResultStatistics corner: A guide to appropriate use of correlation coefficient in medical research.
(2012) · Europe PMC (PubMed Central) · Cited by 4,239
Delivering nanomedicine to solid tumors
Jain, R. K., & Stylianopoulos, T. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.139 · Cited by 3,180
Maeda, H., Nakamura, H., & Fang, J. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.10.002 · Cited by 2,376
Prabhakar, U., Maeda, H., Jain, R. K., Sevick-Muraca, E. M., Zamboni, W., Farokhzad, O. C., Barry, S. T., Gabizon, A., Grodzinski, P., & Blakey, D. C. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4561 · Cited by 1,485
Self-citationNormalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to Biomarkers
Jain, R. K. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.3653 · Cited by 1,248
Liu, J., Liao, S., Diop-Frimpong, B., Chen, W., Goel, S., Naxerova, K., Ancukiewicz, M., Boucher, Y., Jain, R. K., & Xu, L. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1117610109 · Cited by 330
Best Practices in Cancer Nanotechnology: Perspective from NCI Nanotechnology Alliance
Zamboni, W. C., Torchilin, V., Patri, A. K., Hrkach, J., Stern, S., Lee, R., Nel, A., Panaro, N. J., & Grodzinski, P. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2938 · Cited by 275
Self-citationA Safe‐by‐Design Strategy towards Safer Nanomaterials in Nanomedicines
Yan, L., Zhao, F., Wang, J., Zu, Y., Gu, Z., & Zhao, Y. (2019) · Advanced Materials · doi:10.1002/adma.201805391 · Cited by 183 · cited 1×
“In 2017 alone, there were more than 300 nanomedicine patent filings, with more than half related to drug delivery (3).”
BackgroundConcept and Clinical Evaluation of Carrier-Mediated Anticancer Agents
Zamboni, W. C. (2008) · The Oncologist · doi:10.1634/theoncologist.2007-0180 · Cited by 173 · cited 1×
“Examples of various types of NPs include liposomes, polymeric micelles, fullerenes, carbon nanotubes, quantum dots, nanoshells, polymers, dendrimers, and conjugates, including antibody-drug conjugates (9).”
BackgroundSelf-citation
Cited by
Engineering precision nanoparticles for drug delivery
Mitchell, M. J., Billingsley, M. M., Haley, R. M., Wechsler, M. E., Peppas, N. A., & Langer, R. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0090-8 · Cited by 7,933
Polymeric Nanoparticles for Drug Delivery
Beach, M. A., Nayanathara, U., Gao, Y., Zhang, C., Xiong, Y., Wang, Y., & Such, G. K. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00705 · Cited by 1,155
Hwang, D., Ramsey, J. D., & Kabanov, A. V. (2020) · Advanced drug delivery reviews · doi:10.1016/j.addr.2020.09.009 · Cited by 699
Self-citationThe Use of Alternative Strategies for Enhanced Nanoparticle Delivery to Solid Tumors
Izci, M., Maksoudian, C., Manshian, B. B., & Soenen, S. J. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00779 · Cited by 506
Obstacles and opportunities in a forward vision for cancer nanomedicine
de Lázaro, I., & Mooney, D. J. (2021) · Nature Materials · doi:10.1038/s41563-021-01047-7 · Cited by 439
Artificial exosomes for translational nanomedicine
Li, Y.-J., Wu, J.-Y., Liu, J., Xu, W., Qiu, X., Huang, S., Hu, X.-B., & Xiang, D.-X. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-00986-2 · Cited by 303
“7% of systemically administered NPs can reach the tumor mass [20], despite arguments in a recent reanalysis [21].”
BackgroundControlling the biodistribution and clearance of nanomedicines
Cabral, H., Li, J., Miyata, K., & Kataoka, K. (2023) · Nature Reviews Bioengineering · doi:10.1038/s44222-023-00138-1 · Cited by 303
“Comparing conventional pharmacokinetic parameters, such as the AUC for tumour tissue versus that of plasma per animal, revealed 40% higher concentrations of nanomedicines in tumours than in plasma 150 .”
New opportunities and old challenges in the clinical translation of nanotheranostics
Gawne, P. J., Ferreira, M., Papaluca, M., Grimm, J., & Decuzzi, P. (2023) · Nature Reviews Materials · doi:10.1038/s41578-023-00581-x · Cited by 255
“They found that the AUC tumour /AUC blood ratio was ~100 times higher than the tumour %ID 120 .”
BackgroundEjigah, V., Owoseni, O., Bataille-Backer, P., Ogundipe, O. D., Fisusi, F. A., & Adesina, S. K. (2022) · Polymers · doi:10.3390/polym14132601 · Cited by 234
“Similarly, another study [38] performed a reanalysis on the same data set used by Wilhelm et al.”
ResultStealth and pseudo-stealth nanocarriers
Wen, P., Ke, W., Dirisala, A., Toh, K., Tanaka, M., & Li, J. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114895 · Cited by 201
Lin, Z., Chou, W.-C., Cheng, Y.-H., He, C., Monteiro-Riviere, N. A., & Riviere, J. E. (2022) · International Journal of Nanomedicine · doi:10.2147/ijn.s344208 · Cited by 199
“7% of median injected dose).(4,5,10) To address the former issue, physiologically based pharmacokinetic (PBPK) models were developed to simulate the biodistribution of different NPs in healthy rodents and humans.”
BackgroundNanoscale porous organic polymers for drug delivery and advanced cancer theranostics
Singh, N., Son, S., An, J., Kim, I., Choi, M., Kong, N., Tao, W., & Kim, J. S. (2021) · Chemical Society Reviews · doi:10.1039/d1cs00559f · Cited by 208
Applications and challenges of ultra-small particle size nanoparticles in tumor therapy
Xu, J., Song, M., Fang, Z., Zheng, L., Huang, X., & Liu, K. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.12.028 · Cited by 185
Towards principled design of cancer nanomedicine to accelerate clinical translation
Souri, M., Soltani, M., Moradi Kashkooli, F., Kiani Shahvandi, M., Chiani, M., Shariati, F. S., Mehrabi, M. R., & Munn, L. L. (2022) · Materials Today Bio · doi:10.1016/j.mtbio.2022.100208 · Cited by 159
Meta-Analysis of Nanoparticle Distribution in Tumors and Major Organs in Tumor-Bearing Mice
Chen, Q., Yuan, L., Chou, W., Cheng, Y., He, C., Monteiro-Riviere, N. A., Riviere, J. E., & Lin, Z. (2023) · ACS Nano · doi:10.1021/acsnano.3c04037 · Cited by 147
“Price et al. (2020) 10 reanalyzed the NP tumor delivery data from the Wilhelm et al. study 5 with other parameters (e.g., the maximum observed concentration [ C max ] and area under the curve ratio [AUC tumor /AUC blood ratio]).”
Mi, K., Chou, W., Chen, Q., Yuan, L., Kamineni, V. N., Kuchimanchi, Y., He, C., Monteiro-Riviere, N. A., Riviere, J. E., & Lin, Z. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.08.015 · Cited by 138
Symphony of nanomaterials and immunotherapy based on the cancer–immunity cycle
Li, Q., Shi, Z., Zhang, F., Zeng, W., Zhu, D., & Mei, L. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.05.031 · Cited by 138
Nanotoxicology and nanomedicine: The Yin and Yang of nano-bio interactions for the new decade
Bondarenko, O. M., Mortimer, M., Kahru, A., Feliu, N., Javed, I., Käkinen, A., Lin, S., Xia, T., Song, Y., Davis, T. P., et al. (2021) · Nano Today · doi:10.1016/j.nantod.2021.101184 · Cited by 132
Nexus between in silico and in vivo models to enhance clinical translation of nanomedicine
Moradi Kashkooli, F., Soltani, M., Souri, M., Meaney, C., & Kohandel, M. (2021) · Nano Today · doi:10.1016/j.nantod.2020.101057 · Cited by 120
Targeting endothelial permeability in the EPR effect
Lahooti, B., Akwii, R. G., Zahra, F. T., Sajib, M. S., Λάμπρου, Μ., Alobaida, A., Lionakis, M. S., Mattheolabakis, G., & Mikelis, C. M. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.07.039 · Cited by 119
The Future of Tissue-Targeted Lipid Nanoparticle-Mediated Nucleic Acid Delivery
Kularatne, R. N., Crist, R. M., & Stern, S. T. (2022) · Pharmaceuticals · doi:10.3390/ph15070897 · Cited by 109
“systemic drug exposure in comparison to conventional drug formulations [65,66]; these data would support the reduced toxicity of nanomedicines, which generally correlates with systemic exposure, but also reduced efficacy, which correlates to tumor exposure.”
ResultSelf-citationMetal-phenolic networks for cancer theranostics
Liu, P., Shi, X., Zhong, S., Peng, Y., Qi, Y., Ding, J., & Zhou, W. (2021) · Biomaterials Science · doi:10.1039/d0bm02064h · Cited by 106
Deformable nanocarriers for enhanced drug delivery and cancer therapy
Cao, Z., Liu, J., & Yang, X. (2024) · Exploration · doi:10.1002/exp.20230037 · Cited by 111
Chen, L., Huang, Q., Zhao, T., Sui, L., Wang, S., Xiao, Z., Nan, Y., & Ai, K. (2021) · Redox Biology · doi:10.1016/j.redox.2021.102046 · Cited by 105
“Very recently, Lauren et al. argued that non-standard calculations was used by Stefan Wilhelm may produce misleading and biased results [158].”
Islam, R., Maeda, H., & Fang, J. Q. (2021) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2021.1874916 · Cited by 100
“and co-workers [100] revealed that the value 0.”
BackgroundResultShape Transformable Strategies for Drug Delivery
Jia, W., Wang, Y., Liu, R., Yu, X., & Gao, H. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202009765 · Cited by 93
Design of Polymeric Carriers for Intracellular Peptide Delivery in Oncology Applications
Lv, S., Sylvestre, M., Prossnitz, A. N., Yang, L. F., & Pun, S. H. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00963 · Cited by 96
Exploring and Analyzing the Systemic Delivery Barriers for Nanoparticles
Wang, L., Quine, S., Frickenstein, A. N., Lee, M., Yang, W., Sheth, V. M., Bourlon, M. D., He, Y., Lyu, S., Garcia‐Contreras, L., et al. (2023) · Advanced Functional Materials · doi:10.1002/adfm.202308446 · Cited by 101
Toward the scale-up production of polymeric nanotherapeutics for cancer clinical trials
Mahmud, M. M., Pandey, N., Winkles, J. A., Woodworth, G. F., & Kim, A. J. (2024) · Nano Today · doi:10.1016/j.nantod.2024.102314 · Cited by 84
DuRoss, A. N., Landry, M. R., Thomas, C. R., Neufeld, M. J., & Sun, C. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.11.021 · Cited by 77
Covalent Organic Frameworks: Opportunities for Rational Materials Design in Cancer Therapy
Zhou, L., Guan, Q., & Dong, Y. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202314763 · Cited by 75
Bioorthogonal in situ assembly of nanomedicines as drug depots for extracellular drug delivery
Cao, Z., Li, D., Zhao, L., Liu, M., Ma, P., Luo, Y., & Yang, X. (2022) · Nature Communications · doi:10.1038/s41467-022-29693-8 · Cited by 76
Membrane-wrapped nanoparticles for photothermal cancer therapy
Aboeleneen, S. B., Scully, M. A., Harris, J. C., Sterin, E. H., & Day, E. S. (2022) · Nano Convergence · doi:10.1186/s40580-022-00328-4 · Cited by 73
“Independent of the type of surface modification, evidence has shown that only a limited amount (< 5%) of IVadministered NPs successfully reach tumors [24, 37].”
BackgroundHarnessing bacteria for tumor therapy: Current advances and challenges
Guo, L., Ding, J., & Zhou, W. (2023) · Chinese Chemical Letters · doi:10.1016/j.cclet.2023.108557 · Cited by 83
Gawali, P., Saraswat, A. L., Bhide, S., Gupta, S., & Patel, K. R. (2023) · Nanomedicine · doi:10.2217/nnm-2022-0257 · Cited by 75
Cancer-Nano-Interaction: From Cellular Uptake to Mechanobiological Responses
Kashani, A. S., & Packirisamy, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179587 · Cited by 66
“In the targeted therapy, nanoparticles (NPs) with specific properties, nanomedicine, are designed to specifically transport therapeutic agents to tumor sites and to release under controlled conditions [10].”
BackgroundMethodRen, X., Han, Y., Xu, Y., Liu, T., Cui, M., Xia, L., Li, H., Gu, Y., & Wang, P. (2020) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2020.213676 · Cited by 65
Challenges in the development of nanoparticle‐based imaging agents: Characterization and biology
Crist, R. M., Dasa, S. S. K., Liu, C. H., Clogston, J. D., Dobrovolskaia, M. A., & Stern, S. T. (2020) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1665 · Cited by 65
Self-citationDeshmukh, R., Sethi, P., Singh, B., Shiekmydeen, J., Salave, S., Patel, R. J., Ali, N., Rashid, S., Elossaily, G. M., & Kumar, A. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16081076 · Cited by 72
“A recent study has shown that quantifying NP distribution using non-standard techniques might lead to deceptive results, which could have caused bias [46]; therefore, it is vital to be aware of the limitations of these generalised findings.”
BackgroundNucleic acid-based drugs for patients with solid tumours
Huayamares, S. G., Loughrey, D., Kim, H., Dahlman, J. E., & Sorscher, E. J. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00883-1 · Cited by 61
“Moreover, a comprehensive analysis of the performance of nanoparticle delivery technology indicates that, on average, only ~0.7% of systemically administered doses can enter solid tumours 161 , although the accuracy of this estimate has been questioned 163,164 .”
InfluentialTreating Alzheimer’s disease using nanoparticle-mediated drug delivery strategies/systems
Roghani, A. K., Garcia, R. I., Roghani, A., Reddy, A. P., Khemka, S., Reddy, R. P., Pattoor, V., Jacob, M., Reddy, P. H., & Sehar, U. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102291 · Cited by 57
The Role of in silico Research in Developing Nanoparticle-Based Therapeutics
Jayasinghe, M. K., Lee, C. Y., Tran, T., Tan, R., Chew, S. M., Yeo, B. Z. J., Loh, W. X., Pirisinu, M., & Le, M. T. N. (2022) · Frontiers in Digital Health · doi:10.3389/fdgth.2022.838590 · Cited by 57
“As we have described before, NPs present many advantages when used as drug carriers, as they are able to reduce the side effects of many drugs, increase drug half-life in circulation and improve drug accumulation at the target sites inside the body (54, 55).”
BackgroundYouden, B., Jiang, R., Carrier, A. J., Servos, M. R., & Zhang, X. (2022) · ACS Nano · doi:10.1021/acsnano.2c06337 · Cited by 56
Biomimetic Mesoporous Silica Nanoparticles for Enhanced Blood Circulation and Cancer Therapy
Peng, H., Xu, Z., Wang, Y., Feng, N., Yang, W., & Tang, J. (2020) · ACS Applied Bio Materials · doi:10.1021/acsabm.0c01014 · Cited by 53
Souri, M., Kiani Shahvandi, M., Chiani, M., Moradi Kashkooli, F., Farhangi, A., Mehrabi, M. R., Rahmim, A., Savage, V. M., & Soltani, M. (2023) · Drug Delivery · doi:10.1080/10717544.2023.2186312 · Cited by 47
“…tumor penetration; hyperthermia; multi-stage delivery system; focused ultrasound; temperature-sensitive nanoparticles; pH-responsive nanoparticles specific transvascular mechanism, have shown that the accumulation of particles in the tissue is very poor (Dai et al., 2018; Price et al., 2020).”
BackgroundCharge-Switchable nanoparticles to enhance tumor penetration and accumulation
Souri, M., Golzaryan, A., & Soltani, M. (2024) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2024.114310 · Cited by 47
Souri, M., Moradi Kashkooli, F., & Soltani, M. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03255-5 · Cited by 44
Zhang, Y., Xia, Q., Wu, T. S., He, Z., Li, Y., Li, Z., Hou, X., He, Y., Ruan, S., Wang, Z., et al. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-00977-3 · Cited by 45
“The reliability of passive tumor-targeted drug delivery using nanoparticles with enhanced permeability and retention (EPR) remains controversial [18].”
BackgroundPharmacokinetic behaviors of soft nanoparticulate formulations of chemotherapeutics
Sarkar, M., Wang, Y., Ekpenyong, O., Liang, D., & Xie, H. (2022) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1846 · Cited by 41
Liu, J., Guo, L., Mi, Z., Liu, Z., Rong, P., & Zhou, W. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.06.030 · Cited by 40
Micro and nanotechnologies: The little formulations that could
Stiepel, R. T., Duggan, E., Batty, C. J., & Ainslie, K. M. (2022) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10421 · Cited by 43
“They can stack and form doughnut shaped NPs.”
BackgroundInfluentialAdvanced bioanalytical techniques for pharmacokinetic studies of nanocarrier drug delivery systems
Meng, X., Yao, J., & Gu, J. (2024) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2024.101070 · Cited by 40
Piscatelli, J. A., Ban, J., Lucas, A. T., & Zamboni, W. C. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13010114 · Cited by 35
Self-citationNanomedicine Reformulation of Chloroquine and Hydroxychloroquine
Stevens, D. M., Crist, R. M., & Stern, S. T. (2020) · Molecules · doi:10.3390/molecules26010175 · Cited by 35
Self-citationRaval, H., & Bhattacharya, S. (2024) · Current Medicinal Chemistry · doi:10.2174/0109298673302510240328050115 · Cited by 38
Ke, W., Crist, R. M., Clogston, J. D., Stern, S. T., Dobrovolskaia, M. A., Grodzinski, P. A., & Jensen, M. A. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114591 · Cited by 36
Self-citationHighway to Success—Developing Advanced Polymer Therapeutics
Ashford, M. B., England, R., & Akhtar, N. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202000285 · Cited by 35
Metronomic Anti-Cancer Therapy: A Multimodal Therapy Governed by the Tumor Microenvironment
Muñoz, R., Girotti, A., Hileeto, D., & Arias, F. J. (2021) · Cancers · doi:10.3390/cancers13215414 · Cited by 34
Light‐Directed Self‐Powered Metal‐Organic Framework Based Nanorobots for Deep Tumor Penetration
Zhang, X., Wu, L., Chen, X., Liu, C., Wang, Y., Liu, R., & Wang, B. (2024) · Advanced Materials · doi:10.1002/adma.202415121 · Cited by 29
Tian, Y., Ding, Z., Zheng, X., Li, Y., Teng, X., Guo, G., Wang, J., Tan, W. L., & Zhou, B. (2023) · Microporous and Mesoporous Materials · doi:10.1016/j.micromeso.2023.112562 · Cited by 29
Smart CAR-T Nanosymbionts: archetypes and proto-models
Baena, J. C., Victoria, J. S., Toro-Pedroza, A., Aragón, C. C., Ortiz‐Guzman, J., García-Robledo, J. E., Torres, D., Ríos-Serna, L. J., Albornóz, L. L., Rosales, J. D., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1635159 · Cited by 28
Revisiting the outstanding questions in cancer nanomedicine with a future outlook
Sudheesh, M. S., Pavithran, K., & Sabitha, M. (2021) · Nanoscale Advances · doi:10.1039/d1na00810b · Cited by 27
pH-Sensitive Targeting of Tumors with Chemotherapy-Laden Nanoparticles: Progress and Challenges
Imtiyaz, Z., He, J., Leng, Q., Agrawal, A. K., & Mixson, A. J. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14112427 · Cited by 29
“, AUC) may be more predictive of accumulation and therapy [104].”
BackgroundImpact of Nanomedicine in Women's Metastatic Breast Cancer
Ashkarran, A. A., Lin, Z., Rana, J., Bumpers, H. L., Sempere, L. F., & Mahmoudi, M. (2023) · Small · doi:10.1002/smll.202301385 · Cited by 30
Zhang, Z., Tang, Y., Luo, D., Qiu, J. L., & Chen, L. (2025) · APL Bioengineering · doi:10.1063/5.0244706 · Cited by 26
Zhou, D., Shan, S., Chen, L., Li, C., Wang, H., Lu, K., Ge, J., Wang, N., Afshari, M. J., Zhang, Y., et al. (2024) · Advanced Science · doi:10.1002/advs.202401351 · Cited by 25
Prospects for the Use of Metal-Based Nanoparticles as Adjuvants for Local Cancer Immunotherapy
Николаевна, Н. И., Tomasello, B., Attanasio, F., & Pleshkan, V. V. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15051346 · Cited by 25
“This context challenges our current rationale for the development of cancer nanomedicines, but it suggests that an understanding of these pathways will unlock strategies for increasing tumor drug uptake [82].”
BackgroundProgress and potential of nanobubbles for ultrasound-mediated drug delivery
Chen, L. E., Nittayacharn, P., & Exner, A. A. (2025) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2025.2505044 · Cited by 22
Bhattacharjee, S., & Brayden, D. J. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1826434 · Cited by 23
Bioorthogonal chemistry-driven anticancer nanotherapeutics
Zhang, H., Wang, J., Han, R., Sun, B., & Luo, C. (2023) · Trends in Chemistry · doi:10.1016/j.trechm.2023.05.006 · Cited by 20
Wang, Y., Gao, N., Li, X., Ling, G., & Zhang, P. (2024) · Drug Delivery and Translational Research · doi:10.1007/s13346-023-01500-x · Cited by 20
“Research has shown that NPs with hydrodynamic diameters below 10 nm have higher tumor delivery efficiency [26].”
The Role of Optical Imaging in Translational Nanomedicine
Hesemans, E., Buttiens, K., Manshian, B. B., & Soenen, S. J. (2022) · Journal of Functional Biomaterials · doi:10.3390/jfb13030137 · Cited by 19
“Some authors made different calculations, more in line with classical pharmacokinetics, and concluded that the efficiency was better than presented in the original meta-analysis, but this re-analysis only calculated the ratio of NPs in the tumor and in the blood [48].”
ResultNanoparticle Detection in Biology and Medicine: A Review
Kolesnikova, O. A., Shikvin, D. A., Antonova, A. O., Iureva, A. M., Komedchikova, E. N., Obozina, A. S., Kachan, V., Svetlakova, A. V., Kukushkin, I. D., & Shipunova, V. O. (2025) · Biosensors · doi:10.3390/bios15120809 · Cited by 18
Izci, M., Maksoudian, C., Goncalves, F. R., Aversa, L., Salembier, R., Sargsian, A., Gilabert, I. P., Chu, T., Ríos‐Luci, C., Bolea‐Fernandez, E., et al. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01727-9 · Cited by 19
“To this end, the % injected dose would provide a strong and powerful value that has been frequently used in past studies and focusses on the total level of NMs present in the tumor, therefore also indicating the high level of NMs that end up elsewhere (typically in RES organs) which should then be carefully checked fo…”
BackgroundMethodInfluentialSubcutaneous delivery of a dendrimer-BH3 mimetic improves lymphatic uptake and survival in lymphoma
Feeney, O. M., Ardipradja, K., Noi, K. F., Mehta, D. C., Rose, R. D., Yuen, D., Johnston, A. P. R., Kingston, L. P., Ericsson, C., Elmore, C. S., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.05.041 · Cited by 16
Meta-analysis of material properties influencing nanoparticle plasma pharmacokinetics
Macedo, B., Patel, M. N., Zaleski, M. H., Mody, P., Ma, X., Mei, P., Myerson, J. W., Brenner, J. S., & Glassman, P. M. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.122951 · Cited by 16
Nanoparticles of VAV1 siRNA combined with LL37 peptide for the treatment of pancreatic cancer
Agbaria, M., Jbara-Agbaria, D., Grad, E., Ben-David-Naim, M., Aizik, G., & Golomb, G. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.01.084 · Cited by 16
Ma, H., Xing, F., Zhou, Y., Yu, P., Luo, R., Xu, J., Xiang, Z., Rommens, P. M., Duan, X., & Ritz, U. (2023) · Journal of Materials Chemistry B · doi:10.1039/d3tb01008b · Cited by 15
Quantifying nanoparticle delivery: challenges, tools, and advances
Corral, M. Y. M., Alvarez, D. E., & Poon, W. (2023) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2023.103042 · Cited by 17
Souri, M., Elahi, S., Kashkooli, F. M., Kohandel, M., & Soltani, M. (2024) · npj Systems Biology and Applications · doi:10.1038/s41540-024-00467-w · Cited by 15
“However, some reports suggest that nanoparticles, commonly employed for encapsulation, may not effectively extravasate into tumor tissue 13,14 .”
Ma, Z., Chen, L., Xi, Y., Zhang, K., Liu, Y., Zhong, W., Liu, Y., Zheng, C., & Zhao, Y. (2025) · ACS Nano · doi:10.1021/acsnano.5c08499 · Cited by 14
Promoting Nanoparticle Delivery Efficiency to Tumors by Locally Increasing Blood Flow There
Fan, F., Xie, B., & Yang, L. (2021) · ACS Applied Bio Materials · doi:10.1021/acsabm.1c00871 · Cited by 14
Xue, W., Lin, X., Xu, L., Trital, A., He, Y., Tang, G., Bai, H., & Chen, S. (2023) · Advanced Materials · doi:10.1002/adma.202304594 · Cited by 14
Huang, X. P., Ding, Y., Gu, J. M., Tao, Y., Wu, X., Luo, Q., Li, Y. X., Cai, X., & Chen, Z. (2024) · Chemical Engineering Journal · doi:10.1016/j.cej.2024.153171 · Cited by 14
From PEGylation to Next-Generation Polymers: Overcoming Biological Barriers—A Review
Iminova, R., Berganayeva, G., Shepilov, D., Almabekova, A., Zhurtbayeva, A., Abdurakhmanova, L., Vassilina, G., Nurmahanova, A., Kairalapova, G., & Dyusebaeva, M. A. (2026) · Molecules · doi:10.3390/molecules31040675 · Cited by 12
“The study thus recommends the use of validated PK endpoints, particularly AUC ratios, for accurate cross-comparison between targeted polymer systems and small-molecule controls in vivo [27].”
Nanotherapies from an oncologist doctor's view
Liu, S., Li, L., Zhang, X., & Meng, Q. (2022) · Smart Materials in Medicine · doi:10.1016/j.smaim.2022.07.005 · Cited by 13
Research progress of metal–CpG composite nanoadjuvants in tumor immunotherapy
Chen, Y., Feng, D., Cheng, Y., Jiang, X., Qiu, L., Zhang, L., Shi, D., & Wang, J. (2025) · Biomaterials Science · doi:10.1039/d4bm01399a · Cited by 10
Dahis, D., Dion, M. Z., Cryer, A. M., Dosta, P., Gilboa, T., Alonso, M., Lewandowski, M., Puigmal, N., Taboada, G. M., Azhari, H., et al. (2023) · Advanced Functional Materials · doi:10.1002/adfm.202301659 · Cited by 11
Bolaños, K., León, D., Jara-Guajardo, P., Contreras, P., Silva-Ancahuail, D., Riveros, A. L., Montano-Peguero, Y., Pérez, D., Araya, E., Kogan, M. J., et al. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s513628 · Cited by 8
Xie, P., Yang, X., Fatima, Z., Yang, R., Sun, H., Xing, Y., Xu, X., Gu, J., Liu, L., & Li, D. (2023) · Analytica Chimica Acta · doi:10.1016/j.aca.2023.342110 · Cited by 8
Refillable nanodrug-capturing systems for extracellular drug delivery and combined cancer therapy
Cao, Z., Hu, L., Zheng, Y., Xiao, Z., Wang, J., Yang, X., & Wang, J. (2025) · Cell Biomaterials · doi:10.1016/j.celbio.2025.100053 · Cited by 7
Research Progress of Hyaluronic Acid-Coated Nanocarriers in Targeted Cancer Therapy
Hou, X., & Zhang, H. (2024) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2024.0143 · Cited by 10
Supramolecular Heterodimer Peptides Assembly for Nanoparticles Functionalization
Mathieu, C., Ghosh, S., Draussin, J., Gasser, A., Jacquot, G., Banerjee, M., Gupta, T. B., Schmutz, M., Mirjolet, C., Tillement, O., et al. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202304250 · Cited by 6
Xiao, Z., Yu, B., Shao, S., Yang, M., Jing, H., Peng, S., Cao, Z., Yang, X., & Wang, J. (2025) · Nano Letters · doi:10.1021/acs.nanolett.5c02733 · Cited by 6
Yu, T., Yuanyuan, L. I., Zhu, J., Sun, Y., Li, Z., Liang, L., Zhu, Y., Dong, T., & Nie, F. (2026) · Chemical Engineering Journal · doi:10.1016/j.cej.2026.172706 · Cited by 5
Covalent Organic Frameworks: Opportunities for Rational Materials Design in Cancer Therapy
Zhou, L., Guan, Q., & Dong, Y. (2023) · Angewandte Chemie · doi:10.1002/ange.202314763 · Cited by 19
Maksoudian, C., Izci, M., Salembier, R., Gilabert, I. P., Goncalves, F. R., Ríos‐Luci, C., Bolea‐Fernandez, E., Vanhaecke, F., Manshian, B. B., & Soenen, S. J. (2023) · ACS Applied Nano Materials · doi:10.1021/acsanm.3c00780 · Cited by 7
Fu, Y., Ge, Y., Yi, S., Peng, Q., Jiang, H., & Zhou, J. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1854700 · Cited by 4
Crist, R. M., Barenholz, Y., Cern, A., Clark, K. N., Cullis, P. R., Dean, C. A., Desai, N., Ferrari, M., Germain, M., Giacomantonio, C. A., et al. (2025) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.70020 · Cited by 5
“…with concerns over the lack of corresponding vascular architecture in preclinical and clinical tumors, difficulty in reproducing preclinical re-sults clinically, and controversial findings of low nanoparticle tumor accumulation (Nichols and Bae 2014; Price et al. 2020; Wilhelm et al. 2016).”
Self-citationSabnis, N. A., Raut, S., Nagarajan, B., Kapic, A., Dossou, A. S., Lothstein, L., Fudala, R., Bunnell, B. A., & Lacko, A. G. (2024) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.3c00429 · Cited by 3
Metadata
- Authors
- Price, L. S. L., Stern, S. T., Deal, A. M., Kabanov, A. V., & Zamboni, W. C.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Nanotechnology Characterization Lab (NCL), Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
- Corresponding author
- Zamboni, William C.
- Venue
- Science Advances
- Published
- 2020-07-17
- Volume
- 6
- Issue
- 29
- Pages
- eaay9249-eaay9249
- ISSN
- 2375-2548 (ISSN-L)
- PMC
- PMC7439617
- OpenAlex
- W3042603832
- Cited by
- 128
- References
- 21
- Citations by year
- 2026: 20 · 2025: 14 · 2024: 21 · 2023: 24 · 2022: 19 · 2021: 21 · 2020: 9
- FWCI
- 4.81
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Science Advances (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Carolina Center of Cancer Nanotechnology Excellence, University of North Carolina - Chapel Hill (1U54CA19899-01 Pilot Grant)
- Carolina Cancer Nanotechnology Training Program (1T32CA196589, R01CA184088)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Physical Sciences › Physics and Astronomy › Radiation › Radiation Therapy and Dosimetry
- Keywords
- pharmacokinetics, tumor biodistribution, nanotherapeutics, reanalysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.